Formulary Amendments |
Last updated: 16th April 2024 |
Chapter |
Change |
Traffic light status |
Reason for change |
01.05.03 |
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over |
|
NICE TA956
|
02.15 |
Empagliflozin for the treatment of chronic heart failure with preserved or midly reduced ejection fraction |
|
NICE TA929
|
05.01 |
Addition of link to NENC Penicillin Allergy Assessment primary care for adult patients |
|
NENC Medicines Subcommittee Approval
|
13.04 |
Removal of Betnovate N cream |
|
NENC Medicines Subcommittee Approval
|
01.04.02 |
Removal of loperamide oral liquid and amended wording for orodispersible |
|
NENC Medicines Subcommittee Approval
|
01.05.01 |
Shared care guideline link added to sulfasalazine |
|
NENC Medicines Subcommittee Approval
|
01.06.07 |
Addition of chronic constipation in men as an approved indication for prucalopride |
|
NENC Medicines Subcommittee Approval
|
02.02.01 |
Removal of treatment to be initiaited by cardiology |
|
NENC Medicines Subcommittee Approval
|
02.02.03 |
Addition of prescribing guideline for finerenone |
|
NENC Medicines Subcommittee Approval
|
02.03.02 |
Shared care guideline link amended for amiodarone |
|
NENC Medicines Subcommittee Approval
|
02.03.02 |
Shared care guideline link amended for dronedarone |
|
NENC Medicines Subcommittee Approval
|
02.08.01 |
Removal of local guidance for low molecular weight heparins |
|
NENC Medicines Subcommittee Approval
|
02.08.02 |
Removal of Tees Valley Warfarin guidelines for primary care |
|
NENC Medicines Subcommittee Approval
|
02.08.02 |
Removal of NENC DOAC decision support table |
|
NENC Medicines Subcommittee Approval
|
03.04.01 |
Promethazine changed from alternative to second choice |
|
NENC Medicines Subcommittee Approval
|
04.01.01 |
Addition of daridorexant for the treatment of long-term insomnia |
|
NENC Medicines Subcommittee & NICE TA922
|
04.03.03 |
Addition of sertraline 100mg/5ml concentrate for oral solution |
|
NENC Medicines Committee approval
|
04.07.02 |
Addition of fentanyl nasal spray for use by children |
|
NENC Medicines Committee Approval
|
04.07.02 |
Addition of morphie sulfate (MST) 5mg tablets |
|
NENC Medicines Committee Approval
|
04.07.04.02 |
Addition of rimegepant for treating migraine |
|
NICE TA919
|
04.09.01 |
Foslevidopa/foscarbidopa for the treatment of advanced Parkinson’s with motor symptoms in adults |
|
NICE TA934
|
04.09.01 |
Opicapone changed to 1st choice |
|
NENC Medicines Committee Approval
|
04.09.01 |
Bromocriptine - County Durham and Tees Valley shared care guideline removed |
|
NENC Medicines Committee Approval
|
04.09.03 |
Link to riluzole shared care guideline added and formulation changed from orodispersible tablet to orodispersible film |
|
NENC Medicines Committee Approval
|
06.01.02.01 |
Removal of gliclazide MR tablets for new patients |
|
NENC Medicines Committee Approval
|
06.01.02.03 |
Semaglutide (Wegovy). Changed from Brown to Red |
|
NENC Medicines Subcommittee Approval & NICE TA875
|
06.01.02.03 |
Addition of tirzepatide for the treatment of type 2 diabetes |
|
NENC Medicines Subcommittee Approval & NICE TA924
|
06.06.02 |
Denosumab - changed from Green plus to Amber. |
|
NENC Medicines Committee Approval
|
08.01.05 |
Lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults |
|
NICE TA930
|
08.01.05 |
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. Moved from approved to Non-Formulary |
|
NICE TA933
|
08.01.05 |
Idecabtagene vicleucel for treating relapsed and frefractory multuiple myeloma after 3 or more treatments. Added to non-formulary |
|
NICE TA936
|
09.05.02.02 |
Sevelamer and lanthanum changed from Red to Green Plus |
|
NENC Medicines Committee Approval
|
09.08.01 |
Pegunigalsidase alfa for treating Fabry disease |
|
NICE TA915 & NHSE SSC2600
|
10.01.01 |
Celecoxib changed from Green Plus to Green |
|
NENC Medicines Committee Approval
|
11.03.03 |
Ganciclovir ophthalmic gel changed to 1st choice. |
|
NENC Medicines Committee Approval
|
11.04.01 |
Fluocinolone acetonide intravitreal implant for treating chonic diabetic macular oedema |
|
NICE TA953
|
12.03.01 |
Caphosol and Gelclair changed from Red to Green Plus |
|
NENC Medicines Committee Approval
|
13.05.03 |
Baricitinib for treating severe alopecia areata (Not recommended) |
|
NICE TA926
|
15.01.02 |
Removal of desflurane |
|
NENC Medicines Committee Approval
|
About page |
Addition of position statement on the prescribing of branded generic medicines |
|
NENC Medicines Committee Approval
|